Multiple sclerosis (MS) as an auto-immune disease is an inflammatory, demyelinating disease of the central nervous system. Certain genes have shown to be involved in the initiation of MS but the specific role of some of them, e.g. IFNAR1 has not been identified in certain populations yet.
OBJECTIVE:
The IFNAR1 as a type I membrane protein shapes one of the two chains of a receptor for interferons alpha and beta.
METHODS:
To find out how IFNAR1 functions in the Iranian population, the researchers compared the expression level of this gene in relapsing-remitting MS (RR-MS) samples with normal individuals. RNA from the whole blood of 50 RR-MS patients and 50 normal controls were extracted. All patients were HLA-DRB1*15 negative and were responders to interferon-beta with a normal vitamin D level. The level of IFNAR1 gene expression was measured using quantitative RT-PCR.
RESULTS:
According to the results the RR-MS patients manifested a statistically higher expression level of IFNAR1 than their normal counterparts (p= 0.012). Age-wise, females between the ages, 30 to 40 had a significant increase (p= 0.046) but males under 30 showed a statistically meaningful decrease in the expression level (p= 0.04). In terms of sex, only the female patients manifested a statistically significant increase in IFNAR1 (p= 0.004).
CONCLUSIONS:
The overall results show an increase in IFNAR1 level in MS patients treated with IFN-B.
SamarajiwaS.A., WilsonW. and HertzogP.J., Type I interferons: Genetics and structure. The Interferons: Characterization and Application, 2006.
2.
UzeG., SchreiberG., PiehlerJ. and PellegriniS., The receptor of the type I interferon family. Interferon: The 50th Anniversary: Springer, 2007, 71-95.
3.
LamkenP., LataS., GavutisM. and PiehlerJ., Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers, Journal of Molecular Biology341(1) (2004), 303-318.
4.
JaitinD.A., RoismanL.C., JaksE., GavutisM., PiehlerJ., Van der HeydenJ. et al., Inquiring into the differential action of interferons (IFNs): An IFN-α 2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-β , Molecular and Cellular Biology26(5) (2006), 1888-1897.
5.
NovickD., CohenB. and RubinsteinM., The human interferon α β receptor: Characterization and molecular cloning, Cell77(3) (1994), 391-400.
6.
de WeerdN.A., SamarajiwaS.A. and HertzogP.J., Type I interferon receptors: Biochemistry and biological functions, Journal of Biological Chemistry282(28) (2007), 20053-20057.
7.
ToveyM.G., LallemandC. and ThyphronitisG., Adjuvant activity of type I interferons, Biological Chemistry389(5) (2008), 541-545.
8.
ContentJ., Mechanisms of induction and action of interferons, Verhandelingen-Koninklijke Academie voor Geneeskunde van Belgie71(1-2) (2008), 51-71.
9.
FensterlV. and SenG.C., Interferons and viral infections, Biofactors35(1) (2009), 14-20.
10.
McDonaldW.I., CompstonA., EdanG., GoodkinD., HartungH.P., LublinF.D. et al., Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis, Annals of Neurology50(1) (2001), 121-127.
11.
MiloR. and KahanaE., Multiple sclerosis: Geoepidemiology, genetics and the environment, Autoimmunity Reviews9(5) (2010), A387-A94.
12.
IzadiS., NiksereshtA., SharifianM., SahraianM.A., JahromiA.H., AghighiM. et al., Significant increase in the prevalence of multiple sclerosis in iran in 2011, Iranian Journal of Medical Sciences39(2) (2014), 152.
13.
HamedaniS.Y., TaheriM., OmraniM.D., SajjadiE., MazdehM., PanahA.S.T. et al., Up regulation of MMP9 gene expression in female patients with multiple sclerosis, Human Antibodies, 2016, 1-6.
14.
NazdikM.K., TaheriM., OmraniM.D., SajjadiE., Arsang-JangS., KoohparZ.K. et al., Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients, Human Antibodies, 2016, 1-5.
15.
EftekharianM.M., NorooziR., SayadA., SarrafzadehS., ToghiM., AzimiT., KomakiA., MazdehM., InokoH., TaheriM. and MirfakhraieR., RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis, Journal of the Neurological Sciences15(369) (2016 Oct), 259-262.
16.
FarazA., YariR., TaheriM., OmraniM.D., SaberiM., MazdehM. and SayadA., The Relation between Age, Gender and Apoptosis Regulator FasL Gene Expression in Multiple Sclerosis Patients, Journal of Biology and Today's World5(3) (2016 Mar 25), 50-55.
17.
EftekharianM.M., SayadA., OmraniM.D., GhannadM.S., NorooziR., MazdehM., MirfakhraieR., MovafaghA., RoshanaeiG., AzimiT. and InokoH., Single nucleotide polymorphisms in the FOXP3 gene are associated with increased risk of relapsing-remitting multiple sclerosis, Human Antibodies21(Preprint) (2016 Oct), 1-6.
18.
RezazadehM., GharesouranJ., MovafaghA., TaheriM., DarvishH., EmamalizadehB., ShahmohammadibeniN., KhorshidH.K., BehmaneshM., SahraianM.A. and OhadiM., Dominant and protective role of the CYTH4 primate-specific GTTT-repeat longer alleles against neurodegeneration, Journal of Molecular Neuroscience56(3) (2015 Jul 1), 593-596.
19.
TaheriM., NematiS.H., MovafaghA., SaberiM., MirfakhraieR., EftekharianM.M. et al., TRAIL gene expression analysis in multiple sclerosis patients, Human Antibodies, 2016, 33-38.
20.
PolmanC.H., ReingoldS.C., EdanG., FilippiM., HartungH.P., KapposL. et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the ``McDonald Criteria'', Annals of Neurology58(6) (2005), 840-846.
21.
MazdehM., TaheriM., SayadA., BahramS., OmraniM.D., MovafaghA. et al., HLA genes as modifiers of response to IFN-β -1a therapy in relapsing-remitting multiple sclerosis, Pharmacogenomics17(5) (2016), 489-498.
22.
LeyvaL., FernándezO., FedetzM., BlancoE., FernándezV.E., OliverB. et al., IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response, Journal of Neuroimmunology163(1) (2005), 165-171.
23.
ItoK., TanakaH., ItoT., SultanaT.A., KyoT., ImanakaF. et al., Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia, European Journal of Haematology73(3) (2004), 191-205.
24.
SaitoT., JiG., ShinzawaH., OkumotoK., HattoriE., AdachiT. et al., Genetic variations in humans associated with differences in the course of hepatitis C, Biochemical and Biophysical Research Communications317(2) (2004), 335-341.
25.
AmbrusJ.L., DembinskiW., SykesD.E., AkhterS., KulaylatM.N., IslamA. et al., Free interferon-α /β receptors in the circulation of patients with adenocarcinoma, Cancer98(12) (2003), 2730-2733.
26.
MoritaK., TanakaK., SaitoS., KitamuraT., KondoM., SakaguchiT. et al., Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection, Journal of Clinical Gastroenterology26(2) (1998), 135-140.
27.
FukudaR., IshimuraN., IshiharaS., TokudaA., SatohS., SakaiS. et al., Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: Relation to effectiveness of interferon therapy, Journal of Gastroenterology31(6) (1996), 806-811.
28.
MassirerK.B., HirataM.H., SilvaA.E.B., FerrazM., NguyenN.Y. and HirataR.D.C., Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C, Brazilian Journal of Medical and Biological Research37(5) (2004), 643-647.
29.
OliverB., MayorgaC., FernándezV., LeyvaL., LeónA., LuqueG. et al., Interferon receptor expression in multiple sclerosis patients, Journal of Neuroimmunology183(1) (2007), 225-231.
30.
SeranaF., SottiniA., GhidiniC., ZanottiC., CapraR., CordioliC. et al., Modulation of IFNAR1 mRNA expression in multiple sclerosis patients, Journal of Neuroimmunology197(1) (2008), 54-62.
31.
ZoonK.C., ArnheiterH., Zur NeddenD., FitzgeraldD.J. and WillinghamM.C., Human interferon alpha enters cells by receptor-mediated endocytosis, Virology130(1) (1983), 195-203.
32.
LauA., HanniganG., FreedmanM. and WilliamsB., Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy, Journal of Clinical Investigation77(5) (1986), 1632.
33.
BillardC., FerbusD., DiezR., KolbJ., MathiotC., BelangerC. et al., Correlation between the biological and therapeutic effects of interferon-alpha in low-grade nodular non-Hodgkin's lymphoma: Lack of in vivo down-regulation and reduced affinity of IFN-α receptors in unresponsive patients, Leukemia Research15(2) (1991), 121-8.
